Business Blockbuster - Helpng business to be more visible on Google

Business Daily Media


.

Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing the total Series D Financing to $95 Million

HIGHLIGHTS:
  • In challenging market conditions, Insilico Medicine closed Series D2 round, bringing the total Series D financing to $95 million from global investors with expertise in investing in the biopharmaceutical and life sciences sectors.
  • Series D2 round is led by Prosperity7, the diversified growth fund of Aramco Ventures, which is an investment subsidiary of Aramco, the world's leading integrated energy and chemicals company
  • The investment from Prosperity7 will further support Insilico Medicine's Environmental, Social and Governance(ESG)objectives that span beyond biomedicine to actively address global climate change and support sustainable development of ecosystems

HONG KONG SAR - Media OutReach - 11 August 2022 - Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has received Series D2 financing round, led by Prosperity7 Ventures, the diversified growth fund of Aramco Ventures, bringing the total Series D financing to $95 million. This round is also participated by other global investors with expertise in investing in the biopharmaceutical and life sciences sectors.

The financing brought in Prosperity7 as a new investor, alongside current investors in the Series D round, including a large, diversified asset management firm on the US West Coast, B Capital Group, Warburg Pincus, BHR Partners, Qiming Venture Partners, Deerfield, Pavilion Capital, BOLD Capital Partners and WS Investment Company. Insilico's founder and CEO, Alex Zhavoronkov, PhD, also invested in the Series D round.

Aysar Tayeb, Executive Managing Director of Prosperity7 Ventures, said: "The deepening application of AI and machine learning for drug discovery has demonstrated a transformative positive impact on the pharmaceutical industry and we are delighted to embark on this partnership with Insilico Medicine, a frontrunner in this innovation. Backed by the breadth of Aramco's ecosystem across geographies and sectors, we look to support the company to scale up and expand its footprint globally, to drive biotechnology excellence, and to bring positive impact for greater wellbeing."

The new Series D capital will support the continued advancement of Insilico's pipeline, including its lead program which is currently in a Phase 1 study in New Zealand and in China, as well as several pipeline programs in IND-enabling studies. The proceeds will also fund other key strategic initiatives, including further development of its end-to-end Pharma.AI platform, the launch of a fully automated, AI-driven robotic drug discovery laboratory and biological data factory, and the establishment of regional centers.

Insilico Medicine has multiple Environmental, Social and Governance(ESG)objectives that span beyond biomedicine. The investment from Prosperity7 further diversifies the Company's investor base globally and brings a potential strategic partner with deep expertise in high-performance and environmentally friendly energy R&D. Relying on Prosperity7's global network and generous resources, Insilico will expand its AI capabilities from drug R&D to multiple areas, including sustainable chemistry, green energy, and agriculture to actively address global climate change and support sustainable development of ecosystems. Prior to the launch of ESG strategy, Insilico has already harnessed the power of its platform to accelerate innovation in sustainable agriculture in a multi-year collaboration with Syngenta which validated that Insilico's platform capabilities in AI-enabled multiparameter optimization could create substantial value.

"In 2022 Aramco became the world's most valuable company, and we are deeply honored to receive the investment from their venture capital arm, Prosperity7 which focuses on investment in 'disruptive technology'," said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine. "Our experience in expanding our reach into sustainable agriculture where we collaborate with Syngenta and others demonstrated that the diversity of data and methods and unprecedented scale up allows us to improve our performance in drug discovery. I am certain that the upcoming collaborations with Prosperity7 in the field of sustainable and environmentally friendly chemistry and clean energy solutions will further expand our artificial intelligence capabilities. In addition, after spending time in Saudi Arabia, it is clear that the country is making a giant leap in technology, and we would like to be part of it and help the country realize its vision faster using the latest advances in artificial intelligence."

Through a unique dual-CEO structure, Insilico Medicine is advancing its AI capabilities and drug research and development simultaneously. Recently, the Company promoted Dr. Feng Ren, Insilico's Chief Science Officer (CSO) to the position of co-CEO to drive the company's drug R&D platform. In addition to overseeing drug discovery and development, Dr. Ren will also guide the Company's growing clinical development and will play a leading role in driving business development. During his tenure, the Company has rapidly transformed its pipeline into a robust portfolio of novel, innovative drug candidates, targeting areas with highly unmet needs. Seven programs in its internal pipeline have progressed to IND-enabling studies, including a novel 3CL protease inhibitor for COVID-19 treatment, and two synthetic lethality programs targeting MAT2A and USP1 for oncology indications. It also successfully completed a Phase 0 microdose study in Australia and entered Phase I clinical trials with its first internally developed program targeting fibrosis in both New Zealand and China.

"We have the structure in place as an equal parts AI and drug development company," said Feng Ren, PhD, co-CEO and CSO of Insilico Medicine. "We also have a number of exciting initiatives in motion – including an expanding global presence, a robotics lab in development, and significant progress on our internal pipeline programs. With this latest funding round, we will be able to scale up our capabilities, advance our internal programs, develop our AI, and align with partners in the Saudi region to develop new regional technology hubs."

Insilico has co-development and software licensing deals with a number of major pharmaceutical companies. Since the launch of its PandaOmics™ and Chemistry42™ platforms in late 2020, nine out of the top 20 pharmaceutical companies, as measured by 2020 revenue, have used Insilico's AI platforms. In 2022, Insilico signed multi-asset partnerships with Fosun Pharma and EQRX in January and March, respectively. Notably, Insilico achieved its first major milestone and nominated a preclinical candidate for the QPCTL program for cancer immunotherapy less than 40 days into the strategic collaboration with Fosun Pharma. Business development continues to remain a vital part of the company's strategy to demonstrate and unlock the value of its Pharma.AI platform.


Hashtag: #InsilicoMedicine

The issuer is solely responsible for the content of this announcement.

About Insilico Medicine

Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases and aging-related diseases.

For more information, visit

News from Asia

The Hoffman Agency Taps Darren Burns as Asia Pacific President

Appointment builds on the independent consultancy's global ambitionsSILICON VALLEY, USA – Media OutReach Newswire – 17 November 2026 – The Hoffman Agency, an independent global communications cons...

KFC Thailand Breaks Creative Boundaries in 2026 with Bold Campaigns and Its First-Ever Original Manga "Dumb Luck"

Turning Cultural Insights, Pop Culture and Everyday Moments into Unexpected and Unforgettable Brand ExperiencesBANGKOK, THAILAND – Media OutReach Newswire – 17 November 2026 – KFC Thailand has bee...

From Black Friday to Christmas: Garvee Unveils a Holiday Gift Guide for the Year-End Shopping Season

ONTARIO, CANADA – Media OutReach Newswire – 17 November 2026 – With Black Friday, Cyber Monday and Christmas just around the corner, it's time to start thinking about gifts for family, friends and...

CHAGEE Grows to Eight Asia Pacific Markets with Brunei Entry; Unveils New Rooted in Tea Store Design

In the new design, tea is not just what CHAGEE serves, but what shapes the spaceSINGAPORE – Media OutReach Newswire – 17 November 2026 – CHAGEE is growing its family in Asia Pacific, opening its f...

Century-Old Guizhou Time-Honored Brand "Laishigang Sauce-Aroma Baijiu" Establishes Foothold in Hong Kong to Launch Southeast Asian and International Expansion Strategy

HONG KONG SAR – Media OutReach Newswire – 17 November 2026 – Guizhou Laishigang Liquor Co., Ltd. ("Laishigang Liquor"), a fifth-generation, century-old sauce-aroma baijiu producer certified as a ...

THE WORLD ENDS 2026 Connects Asia’s Creative and Design Networks to Unlock New Business Opportunities

International design platform brings together creative talent, industry partners and regional business networks, targeting 200 buyer–seller connections to foster business collaboration and cross-bo...

Ayara Kamala Reveals a Refreshed Vision for Wellness in Phuket

BANGKOK, THAILAND – Media OutReach Newswire – 17 November 2026 - Ayara Kamala Resort & Spa, an intimate haven nestled along Phuket's prestigious Kamala coastline, has officially unveiled its r...

China-Indonesia Cultural Industry Exchange Symposium Held in Jakarta

JAKARTA, INDONESIA – Media OutReach Newswire – 17 November 2026 – On the afternoon of November 13, the China-Indonesia Cultural Industry Exchange Symposium, co-hosted by the China Intercontinental...

Disney and Visa Announce Multi-Year Strategic Alliance Across Asia Pacific

The alliance spans Disney-branded card programmes, cardholder benefits and joint marketing initiatives across the regionHONG KONG SAR – Media OutReach Newswire – 17 November 2026 – The Walt Disney...

Galaxy Resort Presents: "Plácido Domingo & José Carreras: The Legends United Opera Gala"

Greater China and Macau's Only Performance Galaxy Rewards select members can enjoy privileged priority booking from 10 December 2026.Tickets go on public sale from 14 December 2026 CaptionMACAU SAR...

Why the secrecy around car insurance?

Every year, millions of Australians receive their car insurance renewal and promise themselves they’ll look at it properly later. Then life gets in ...

Australian workers spend almost an hour a day administering email

Research finds email filing, searching and rework consuming an estimated 58 minutes a day and potentially exposing organisations to millionsAustralian...

Customer Service Is Becoming Part of the Small Business Sales and Marketing Engine

For Customer Service Week, 5-9 October, Thryv is urging small businesses to look beyond generating  enquiries and examine what happens after a custome...

Gift Cards as the gateway to agentic payments

Prepaid and stored value gives consumers the trust and control to try AI shopping agents By Blackhawk Network VP Head of ANZ Kieran Nolan For deca...

Why Data Accumulation Without Governance Undermines Sustainability Goals

In July 2026, Group 2 entities, the second cohort of Australian businesses, began their first reporting period under the mandatory climate disclosur...

Permanent $20,000 Instant Asset Write-Off Gives Small Businesses Greater Planning Certainty

The Federal Government’s decision to permanently legislate the $20,000 instant asset write-off will give eligible small businesses greater certainty...